BUY Jubilant Pharmova Limited — Ventura
byVenturaHorizon: NA (inferred 1 year)15 Jan 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Jubilant Pharmova gets USFDA approval for new fill-and-finish line at Spokane facility
NewsCnbc-Tv18·23 Aug · 2w ago
1 other SEBI-registered advisor has an active long-term BUY call on this stock
Advisor consensus · same horizon·8 Feb · 7mo ago
Here's why these four pharma stocks are in focus today
NewsCnbc-Tv18·24 Aug · 2w ago
Jubilant Pharmova Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026. The results will be posted on the company's website.
NSE · Outcome of Board Meeting·10 Aug · 4w ago
Jubilant Pharmova Ltd's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026. The results and limited review report were filed with the stock exchanges.
BSE · Board Meeting·10 Aug · 4w ago
Long-term trend bearish — 200-day average falling over the past quarter
Technicals · trend·7 Sept · yesterday
Jubilant Pharmova Gets ₹87.31 Crore GST Notice From Mysore Tax Authorities For FY23
NewsGoogle News·1 Sept · 6d ago
Jubilant Pharmova: ₹87 கோடி GST நோட்டீஸ்! அதிரடியாக மறுப்பு தெரிவித்த நிறுவனம்
NewsGoogle News·1 Sept · 6d ago
Jubilant Pharmova faces ₹105.5 Cr GST demand over IGST refund claim
NewsGoogle News·28 Aug · 1w ago
Jubilant Pharmova shares decline 6% after Q1 profits falls 45% YoY
NewsEt-Markets·11 Aug · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.